PATENT COOPERATION TREATY

INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (dayimonthiyear) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below Priority date (day/month/year) International filing date (day/month/year) International application No. 30.10.2003 29.10.2004 PCT/GB2004/004580 International Patent Classification (IPC) or both national classification and IPC A23L1/015, A61K35/78, A23C9/00 Applicant LODERS CROKLAAN BV This opinion contains indications relating to the following items: ☑ Box No. I Basis of the opinion ☐ Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☑ Box No. III Lack of unity of invention ☐ Box No. IV Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Certain documents cited ☐ Box No. VI ☐ Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220. Authorized Officer Name and mailing address of the ISA:

Rinaldi, F

Telephone No. +49 89 2399-7360



European Patent Office

Fax: +49 89 2399 - 4465

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

D-80298 Munich

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/GB2004/004580

_	Box	(No	. I Basis of the opinion			
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.					
		lan	s opinion has been established on the basis of a translation from the original language into the following guage , which is the language of a translation furnished for the purposes of international search der Rules 12.3 and 23.1(b)).			
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
	a type of material:					
	[]	a sequence listing			
	[table(s) related to the sequence listing			
	b. fo	orma	at of material:			
	[in written format			
	. [in computer readable form			
	c. ti	me (of filing/furnishing:			
	(contained in the international application as filed.			
	[filed together with the international application in computer readable form.			
	[furnished subsequently to this Authority for the purposes of search.			
3.		has	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto been filed or furnished, the required statements that the information in the subsequent or additional sies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.			
4.	Add	litior	nal comments:			

International application No. PCT/GB2004/004580

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:						
	the entire international application,					
\boxtimes	☑ claims Nos. 21 in respect of industrial applicability					
because:						
⊠	the said international application, or the said claims Nos. 21 relate to the following subject matter which does not require an international preliminary examination (specify):					
	see separate sheet					
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):					
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.					
	no international search report has been established for the whole application or for said claims Nos.					
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:					
	the written form		has not been furnished			
			does not comply with the standard			
	the computer readable form		has not been furnished			
			does not comply with the standard			
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.					
	See separate sheet for further details					

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N).

Yes: Claims

Claims

1-25

No:

Inventive step (IS)

Yes: Claims

No:

Claims 1-

1-25

Industrial applicability (IA)

Yes: Claims

1-20,22-25

No: Claims

2. Citations and explanations

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 21 of the present application relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to industrial applicability of the said subject-matter of this claim.

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- For the assessment of the subject-matter of present claim 21 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States (see also Item III of the present written opinion). The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable claims directed to a method of medical treatment.
- 2 Reference is made to the following documents:
 - D1: US-A-5 607 971 (AL-MAHMOUD MOHSEN ET AL) 4 March 1997 (1997-03-04)
 - D2: US-A-5 466 453 (UCHIDA YUKIO ET AL) 14 November 1995 (1995-11-14)
 - D3: US-A-5 690 984 (LIM JUNG GEUN) 25 November 1997 (1997-11-25)
 - D4: US-B1-6 329 000 (JI LING) 11 December 2001 (2001-12-11)
 - D5: DATABASE FSTA [Online] INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANFURT/MAIN, DE; 2000, EUN-JU KIM ET AL: "Bread properties utilizing extracts of pine needle according to preparation method." XP002272259 Database accession no. 2000-00-m0004
 - D6: DATABASE FSTA [Online] INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANFURT/MAIN, DE; 1999, YOUNG-AE OH ET AL: "Effect of addition of water extract of pine needle on tissue of kimchi." XP002272260 Database accession no. 1999-00-j0385
 - D7: WO 02/101025 A (KWON JAY YUNE ;KOREA BIOTECH CORP (KR);

VLADIMIR BAKHAREV A (RU)) 19 December 2002 (2002-12-19)

Novelty

The subject matter presently claimed is considered to be novel (Art.33(2) PCT). None of the products of the prior art discloses a pine needle extract comprising less than 0.01% isocupressic acid. Reference is made to p.16 and Table 1 of the present application wherein the content of isocupressic acid has been established for several extracts of the prior art (D1 and D4) and for aqueous pine needle extracts with or without ion exchange and carbon black treatment. Similarly, the use of such extracts or methods applying said extracts as well a process for its production is considered to be novel.

Inventive step

- The subject-matter presently claimed is considered not to fulfil the requirements of Art.33(3) PCT.
- 4.1 D1-D7 (for relevant passages please see ISR) disclose independently of each other the use of pine needle extracts for at least one the following purposes:
 - reducing blood pressure,
 - preparing healthy food products (such as ice cream),
 - preparing healthy fermented dairy food products
 - preventing hypertension or at least having health indications
 - improving the taste and texture of various food compositions.
 - Said documents, however, fail to disclose less than 0.01% of isocupressic acid in spite of the fact that the extracts do contain (implicitly or explicitly) at least one organic acids such as for instance shikimic or quinic acid.
- 4.2 The problem to be solved is to provide alternative healthy food compositions, dairy products and beverages and methods / uses therefore.
- 4.3 Starting from each one of the documents of the prior art, no surprising effect can be seen in the solution proposed by the present application, i.e. using pine needle extracts with low isucupressic acid contents. This is in particular valid as far as the technical effect concerns textural or sensoric properties of the products.
- 4.4 Also the assertion on p.2, last paragraph of the application as internationally filed, that it was not known that low isocupressic acid pine needle extracts are therapeutically effective cannot be followed On the contrary, D4 shows that pine needle extracts with particularly low amounts of isocupressic acid are effective against hypertension, diabetes, high blood viscosity, hyperlipidaemia to name a few? From D4 the one skilled in the art can only derive the teaching that low

amounts of isocupressic acid do not influence therapeutic properties of pine needle extracts.

Re Item VIII

Certain observations on the international application

- 1 The following clarity deficiency are noted (Art.6 PCT)
- 1.1 Although claims 11, 19, 21 and 23 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness.
- 1.2 The subject-matter of present claims 3 and 4 is unclear as it is not readily clear to the one skilled in the art what falls within and what is without the ambit of the claim
- 1.3 The subject-matter of present claim 16 is formulated as a result to be achieved.